|Title:||TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Angiosarcoma|
|Session Title:||Poster Session 2 - Soft Tissue Sarcomas - Poster 110|
|Presenter:||K. Kumar Sankhala, M.D., Sarcoma Oncology Research Center, Santa Monica, CA|
|Location:||Corinthia Hotel Lisbon, Lisbon, Portugal|
|Date/Time:||Friday, November 11, 2016, 10:40 AM - 7:00 PM, Western Europe Time|
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced the following presentation at the upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting in Lisbon, Portugal:
About TRC105 (carotuximab) TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.